Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.
Wouter van der BruggenMarlous Hagelstein-RotmanLioe-Fee de Geus-OeiFrits SmitP D Sander DijkstraNatasha M Appelman-DijkstraDennis VriensPublished in: European journal of nuclear medicine and molecular imaging (2019)
Individualized Na18F-PET/CT SUV cutoffs reproducibly discriminated HB from FD and were well-normalized. The strong relations of bone formation serum markers with Na18F-PET/CT FD burden measurements suggest clinical relevance over SBS as an adjunct instrument in FD patients. The correlation of both imaging modalities with increased work-related BPI scores also indicates clinical applicability. Moreover, SBS is known to remain stationary irrespective of use of medication, whereas TLF on Na18F-PET/CT was higher in baseline patients using bisphosphonates. This makes Na18F-PET/CT a promising tool to quantitatively measure treatment efficacy in FD.